INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

AORTIC VALVE-IN-VALVE TAVI

Özgen Şafak

Balıkesir University, Faculty of Medicine, Department of Cardiology, Balıkesir, Türkiye

Şafak Ö. Aortic Valve-in-Valve TAVI. In: Tanık VO, Özlek B, editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.283-294.

ABSTRACT

Valvular heart diseases (VHD), moderate-to-severe, prevalence increased with age. Aortic Stenosis (AS) is the mostly seen VHD in developed countries, whereas mitral valve diseases were still mostly seen in developing countries. In surgically high risk patients with sypmtomatic AS, Transcatheter Aortic Valve Implantation (TAVI) is the another option since 2012 after FDA approved the procedure, and in 2015 FDA approved Valve-in-Vallve (ViV) TAVI in patients with failed surgical bioprosthetic valves. As surgical shift from mechanical-to-bioprosthetic surgical AVR (SAVR) was detected, ViV TAVI rates were increased. Studies demostrated that ViV TAVI was associated with less stroke, pacemaker need, and major bleeding complications and also 1-month mortality rate compared to redo-SAVR. We need more randomized controlled prospective studies to evaluate safety, success and superior clinical outcomes of ViV TAVI procedure.

Keywords: Valvular heart disease; Aortic stenosis; Transcatheter aortic valve implantation; Valve-in-valve

Referanslar

  1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,Enriquez-Sarano M. Burden of valvular heart diseases: a populationbased study. Lancet 2006;368:1005-11. [Crossref]  [PubMed]
  2. Lung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 2011;8:162-72. [Crossref]  [PubMed]
  3. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43. [Crossref]  [PubMed]
  4. Demirbağ R, Sade LE, Aydın M, Bozkurt A, Acartürk E. The Turkish registry of heart valve disease. Turk Kardiyol Dern Ars. 2013;41(1):1-10. [Crossref]  [PubMed]
  5. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62(11):1002-1012. [Crossref]  [PubMed]
  6. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. [Crossref]  [PubMed]
  7. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease [published correction appears in Eur Heart J. 2022 Jun 1;43(21):2022. Eur Heart J. 2022;43(7):561-632. [Link]
  8. Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. The J Thoracic Cardiovasc Surg. 2015;149:1262-1269.e3. [Crossref]  [PubMed]
  9. Caus T, Chabry Y, Nader J, Fusellier JF, De Brux JL. Trends in SAVR with biological vs. mechanical valves in middle-aged patients: results from a French large multicentric survey. Front Cardiovasc Med. 2023;10:1205770. [Crossref]  [PubMed]  [PMC]
  10. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2021;143(5):e228. [Crossref]  [PubMed]
  11. John D. Carroll, Michael J. Mack, Sreekanth Vemulapalli, Howard C. Herrmann, Thomas G. Gleason, George Hanzel. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement, JACC. 2020;76(21):2492-2516 [Crossref]  [PubMed]
  12. Edelman JJ, Khan JM, Rogers T, et al. Valve-in-Valve TAVR: State-of-the-Art Review. Innovations (Phila). 2019;14(4):299-310. [Crossref]  [PubMed]
  13. Webb JG, Dvir D. Transcatheter aortic valve replacement for bioprosthetic aortic valve failure: the valve-in-valve procedure. Circulation. 2013;127(25):2542-2550. [Crossref]  [PubMed]
  14. Généreux P, Piazza N, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825-1857. [Crossref]  [PubMed]
  15. Rodriguez-Gabella T, Voisine P, Dagenais F, et al. Long-term outcomes following surgical aortic bioprosthesis implantation. J Am Coll Cardiol. 2018;71:1401-1412 [Crossref]  [PubMed]
  16. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162-170. [Link]
  17. Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC, et al. Transcatheter ViV Versus Redo Surgical AVR for the Management of Failed Biological Prosthesis: Early and Late Outcomes in a Propensity-Matched Cohort. JACC Cardiovasc Interv. 2020;13:765-74 [Crossref]  [PubMed]
  18. Deharo P, Bisson A, Herbert J, Lacour T, Etienne CS, Porto A, et al. Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement. J Am Coll Cardiol. 2020;76:489-99. [Crossref]  [PubMed]
  19. Thandra A, Abusnina W, Jhand A, Shaikh K, Bansal R, Pajjuru VS, et al. Valve-in-valve transcatheter aortic valve replacement versus redo surgical valve replacement for degenerated bioprosthetic aortic valve: An updated meta-analysis comparing midterm outcomes. Cardiac Angiography & Interventions, 13 Feb 2021;97(7):1481-1488 [Crossref]  [PubMed]
  20. Tarantini G, Sathananthan J, Fabris T, et al. Transcatheter Aortic Valve Replacement in Failed Transcatheter Bioprosthetic Valves. JACC Cardiovasc Interv. 2022;15(18):1777-1793. [Crossref]  [PubMed]
  21. Webb JG, Mack MJ, White JM, et al. Transcatheter aortic valve implantation within degenerated aortic surgical Bioprostheses: PARTNER 2 valve-in-valve registry. J Am Coll Cardiol. 2017;69:2253-2262. [Crossref]  [PubMed]
  22. Nuche J, Abbas AE, Serra V, et al. Balloon- vs self-expanding transcatheter valves for failed small surgical aortic bioprostheses: 1-year results of the LYTEN trial. JACC Cardiovasc Interv. 2023;16:2999-3012. [Crossref]  [PubMed]
  23. Pibarot P, Simonato M, Barbanti M, et al. Impact of pre-existing prosthesis-patient mismatch on survival following aortic valve-in-valve procedures. JACC Cardiovasc Interv. 2018;11:133-141. [Crossref]  [PubMed]
  24. Dvir D. Treatment of small surgical valves: clinical considerations for Achieving Optimal results in valve-in-valve procedures. JACC Cardiovasc Interv. 2015;8:2034-2036. [Crossref]  [PubMed]
  25. Hashimoto G, Garcia S, Sato H, et al. New insights and perspective on bioprosthetic valve fracture from bench testing and computed tomography analysis. Struct Heart. 2024. [Crossref]  [PubMed]  [PMC]
  26. Aurigemma C, Burzotta F, Vergallo R, et al. Transcatether Aortic Valve Implantation to Treat Degenerated Surgical Bioprosthesis: Focus on the Specific Procedural Challenges. Front Cardiovasc Med. 2022;9:895477. [Crossref]  [PubMed]  [PMC]
  27. Allen KB, Chhatriwalla AK, Saxon JT, et al. Bioprosthetic valve fracture: technical insights from a multicenter study. J Thorac Cardiovasc Surg. 2019;158:1317-1328.e1. [Crossref]  [PubMed]
  28. Chhatriwalla AK, Allen KB, Saxon JT, et al. Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv. 2017;10(7):e005216. [Crossref]  [PubMed]
  29. Meier D, Payne GW, Mostaço-Guidolin LB, et al. Timing of bioprosthetic valve fracture in transcatheter valve-invalve intervention: impact on valve durability and leaflet integrity. EuroIntervention. 2023;18:1165-1177. [Crossref]  [PubMed]  [PMC]
  30. Ribeiro HB, Rodes-Cabau J, Blanke P, et al. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. Eur Heart J. 2018;39:687-695 [Crossref]  [PubMed]
  31. Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 2013; 62:1552-1562. [Crossref]  [PubMed]
  32. Mercanti F, Rosseel L, Neylon A, et al. Chimney stenting for coronary Occlusion during TAVR: insights from the chimney registry. JACC Cardiovasc Interv. 2020;13:751-761. [Crossref]
  33. Khan JM, Dvir D, Greenbaum AB, et al. Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement: concept to first-inHuman. JACC Cardiovasc Interventions. 2018;11:677-689. [Crossref]  [PubMed]  [PMC]
  34. Khan JM, Greenbaum AB, Babaliaros VC, et al. BASILICA trial: one-year outcomes of transcatheter electrosurgical leaflet laceration to prevent TAVR coronary obstruction. Circ Cardiovasc Interv. 2021;14:e010238. [Crossref]  [PubMed]  [PMC]
  35. Danny Dvir, Didier Tchétché, Martin B Leon, Philippe Généreux, Benjamin Seguy. Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study. Eur Heart J 2024;45(33):3031-3041. [Crossref]  [PubMed]  [PMC]
  36. Tarantini G, Dvir D, Tang GHL. Transcatheter aortic valve implantation in degenerated surgical aortic valves. EuroIntervention. 2021;17(9):709-719. [Crossref]  [PubMed]  [PMC]
  37. Alperi A, Rodes-Cabau J, Simonato M, et al. Permanent pacemaker implantation following valve-in-valve transcatheter aortic valve replacement: VIVID registry. J Am Coll Cardiol. 2021;77:2263-2273. [Crossref]  [PubMed]
  38. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in lowrisk patients. New Engl J Med. 2019;380:1706-1715. [Crossref]  [PubMed]